Trial sponsors and CROs must do more to recruit older people, says EU group
Peter Crome from Keele University, UK told Outsourcing-pharma that this under representation means evidence of a drug’s efficacy in older people is an extrapolation of data from trials in younger people, which may not necessarily be applicable.
Professor Crome explained that recognition of this trend was the key motivation for the development of the new PREDICT charter, which was launched last week in a project coordinated by the Medical Economics and Research Centre (MERCS).
Professor Crome also said that sponsors and contract research organisations (CRO) can play more of a role by, for example, working with researchers who have access to older people, or by making greater use of home visits that make participation in trials less time intensive.
